Respiratory Technology Corporation (dba Restech) announced that its revolutionary Dx-pH Measurement System has received CE mark approval, allowing introduction to the European Union and all countries recognizing the CE Mark. This approval from the European Union certifies Restech has met EU health, safety and environmental requirements that ensure consumer safety.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. Food and Drug Administration (FDA) approved KAPIDEX? (dexlansoprazole) delayed release capsules for the once-daily, oral treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE.
Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a new tablet formulation to add to its ZEGERID? family of branded prescription pharmaceutical products. The new formulation is an immediate-release tablet that combines omeprazole, a proton pump inhibitor (PPI), with a mix of buffers.
According to an article published in Archives of Surgery, two non-pharmacological GERD (gastroesophageal reflux disease) treatments seem to be effective in lowering medication use and improving swallowing symptoms as well as the patient's voice. One of the assessed therapies appears to be effective in reducing heartburn and cough. The other one reduces regurgitation. Archives of Surgery is a JAMA/Archives journal.
Addex Pharmaceuticals (SWISS: ADXN), the allosteric modulation company, announced the start of a Phase IIb trial of ADX10059 monotherapy in patients with gastroesophageal reflux disease (GERD), the cause of heartburn and other symptoms. ADX10059 is a first-in- class reflux inhibitor that works by reducing activation of the metabotropic glutamate receptor 5 (mGluR5) through negative allosteric modulation (NAM).
Next Page »